SASankar Arumugam

Sankar Arumugam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sankar Arumugam has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Mark Sidhom

    South Western Clinical School, University of New South Wales, Sydney, NSW, Australia

    6 shared publications
  • Tony Young

    Department of Medical Physics, Liverpool and Macarthur Cancer Therapy Centres and Ingham Institute, New South Wales, Australia

    4 shared publications
  • Darren Pavey

    Department of Medical Physics, Liverpool and Macarthur Cancer Therapy Centres and Ingham Institute, Sydney, NSW, Australia

    2 shared publications
  • David Thwaites

    Institute of Medical Physics, School of Physics, University of Sydney, Sydney, Australia

    2 shared publications
  • Karen Wong

    Department of Medical Physics, Liverpool and Macarthur Cancer Therapy Centres and Ingham Institute, Sydney, NSW, Australia

    2 shared publications
  • Lois Holloway

    South Western Sydney Clinical School, Faculty of Medicine, UNSW, Sydney, Australia

    2 shared publications

Latest Publications

  • Pancreas SBRT requires online adaptive treatment to adequately manage motion

    by Tony Young, Mark Lee, Meredith Johnston, David Thwaites, Lois Holloway, Theresa Nguyen, Rebecca Ko, Sankar Arumugam

  • Open Access

    Impact of Volumetric Modulated Arc Therapy Control Point Discretisation on Dosimetry: A Comparative Evaluation of Two Treatment Planning Systems

    by Sankar Arumugam, Tony Young

    Aim: The aim of the study was to investigate the dose calculation accuracy of volumetric modulated arc therapy (VMAT) control point (CP) discretisation approaches in Pinnacle and RayStation treatment planning systems (TPSs). Methods: The 6MV beam model for Elekta linear accelerator with Agility head generated in Pinnacle and RayStation was used in this study. The impact of CP discretization on dose calculation was assessed using 10 prostate and ten breast VMAT plans generated in each TPS. In Pinnacle, VMAT plans were generated using both 4° and 2° CP gantry spacing, while RayStation plans used 2° spacing. To assess the dosimetric differences due to CP discretization, VMAT plans from Pinnacle were recalculated in RayStation, and vice versa. The impact of CP discretization on target volume and critical structures was assessed by comparing dose volume histogram metrics. The agreement between ArcCheck-measured and TPS-calculated doses was assessed using gamma analysis with a 2%2 mm tolerance criterion. Results: The prostate and breast plans with 2° spacing generated in Pinnacle and recalculated in RayStation showed a mean (Std Dev) target dose agreement of 1.0 (0.4)% and 0.3 (0.8)%, respectively. The similar comparison for RayStation-generated plans recalculated in Pinnacle was 0.8 (0.2)% and 2.4 (0.2)%, respectively. The ArcCheck measurements of Pinnacle-generated prostate and breast plans showed a mean gamma pass rate of 96.5 (1.2)% and 91.5 (5.2)%, respectively. Similarly, RayStation-generated prostate and breast plans had a mean gamma pass rate of 96.7 (2.3)% and 95.4 (3.7)%, respectively. Conclusions: The CP discretization approach implemented in RayStation results in improved dose calculation accuracy of VMAT plans, particularly for plans with larger CP spacing.

  • Enhancing intrafraction position monitoring for prostate radiotherapy on a conventional linear accelerator: an optimization study

    by Sankar Arumugam

    To compare the intrafraction prostate motion monitoring capabilities between intrafraction Cone Beam Computed Tomography (IF-CBCT) and SeedTracker-based real-time monitoring, and to optimize imaging doses in real-time monitoring using the IF-CBCT image acquisition method. Simulations of static and dynamic intrafraction prostate motions were conducted on a phantom using a robotic arm. The study utilized the XVI imaging system of the Elekta linear accelerator for IF-CBCT and SeedTracker-based monitoring during hypofractionation and Stereotactic Body Radiation Therapy (SBRT). The optimal imaging frequency for real-time monitoring was determined by calculating VMAT gantry traverse times. The effective dose resulting from IF-CBCT and SeedTracker-based monitoring approaches were compared. IF-CBCT showed static offsets as seed duplications and the offsets calculated using ‘Seed’ automatic image registration available XVI system depend on the initial position of the seeds in verification and localisation image sets. This dependency resulted in large differences (up to 4.9 mm) between actual and calculated position offsets. Dynamic offsets resulted in blurring or duplication of seeds in IF-CBCT images depending on the type of the dynamic motion. SeedTracker-based real-time monitoring successfully identified position deviation events as they occurred during treatment. For hypofractionation and SBRT treatments, IF-CBCT imaging resulted in an effective dose of 54.3 mSv and 13.6 mSv, respectively. Optimized imaging frequency for real-time monitoring led to a dose reduction of up to 86.2% and 97.2% for hypofractionation and SBRT regimens, respectively, compared to the IF-CBCT approach. SeedTracker real-time monitoring effectively identified target position deviations in real-time, surpassing the capabilities of the IF-CBCT approach. Moreover, the SeedTracker imaging approach significantly reduced imaging doses compared to IF-CBCT.


  • Open Access

    Treatment accuracy of standard linear accelerator-based prostate SBRT: the delivered dose assessment of patients treated within two major clinical trials using an in-house position monitoring system

    by Sankar Arumugam, Tony Young, Catherine Jones, David Pryor, Mark Sidhom

    Background and purpose: The purpose of this study was to assess the dosimetric improvements achieved in prostate stereotactic body radiotherapy (SBRT) treatment within the PROMETHEUS and NINJA trials using an in-house real-time position monitoring system, SeedTracker.Methods and materials: This study considered a total of 127 prostate SBRT patients treated in the PROMETHEUS (ACTRN12615000223538) and NINJA (ACTRN12618001806257) clinical trials. The SeedTracker position monitoring system was utilized for real-time position monitoring with a 3-mm position tolerance. The doses delivered to the clinical target volume (CTV), rectum, and bladder were assessed by incorporating the actual target position during treatment. The dose that would have been delivered without monitoring was also assessed by incorporating the observed position deviations.Results: Treatment with position corrections resulted in a mean (range) CTV D99 difference of −0.3 (−1.0 to 0.0) Gy between the planned and delivered dose. Without corrections, this difference would have been −0.6 (−3.7 to 0.0) Gy. Not correcting for position deviations resulted in a statistically significant difference between the planned and delivered CTV D99 (p < 0.05). The mean (range) dose difference between the planned and delivered D2cc of the rectum and bladder for treatment with position corrections was −0.1 (−3.7 to 4.7) Gy and −0.1 (−1.7 to 0.5) Gy, respectively. Without corrections, these differences would have been −0.6 (−6.1 to 4.7) Gy and −0.2 (−2.5 to 0.9) Gy.Conclusions: SeedTracker improved clinical dose volume compliance in prostate SBRT. Without monitoring and corrections, delivered dose would significantly differ from the planned dose.


  • Open Access

    Robust optimization for prostate radiotherapy: Assessment of delivered dose by incorporating intrafraction prostate position deviations

    by Sankar Arumugam, Mark Sidhom

    Aim To assess the robustness of the dose delivered to the clinical target volume (CTV) using planning target volume (PTV) based and robust optimization planning approaches in localized prostate cancer radiotherapy. Methods Retrospective data of twenty prostate cancer patients, including radiotherapy and real-time prostate position, were analyzed. Two sets of volumetric modulated arc therapy plans were generated per patient: PTV-based and robust optimization. PTV-based planning used 7mm CTV-PTV margin, while robust planning considered same-magnitude position deviations. Differences in CTV D99, PTV D95, bladder and rectum V40, and V60 values were evaluated. The target position, determined by in-house position monitoring system, was incorporated for dose assessment with and without position deviation correction. Results In the robust optimization approach, compared to PTV-based planning, the mean (SD) V40 and V60 values of the bladder were reduced by 5.2% (4.1%) and 5.1% (1.9%), respectively. Similarly, for the rectum, the reductions were 0.8% (0.5%) and 0.6% (0.6%). In corrected treatment scenarios, both planning approaches resulted in a mean (SD) CTV D99 difference of 0.1 Gy (0.1 Gy). In the not corrected scenario, PTV-based planning reduced CTV D99 by 0.1 Gy (0.5 Gy), while robust planning reduced it by 0.2 Gy (0.6 Gy). There was no statistically significant difference observed in the planned and delivered rectum and bladder dose for both corrected and not corrected scenarios. Conclusion Robust optimization resulted in lower V40 and V60 values for the bladder compared to PTV-based planning. However, no difference in CTV dose accuracy was found between the two approaches.

  • Open Access

    Assessment of interfraction dose variation in pancreas SBRT using daily simulation MR images

    by Tony Young, Mark Lee, Meredith Johnston, Theresa Nguyen, Rebecca Ko, Sankar Arumugam

    Pancreatic Cancer is associated with poor treatment outcomes compared to other cancers. High local control rates have been achieved by using hypofractionated stereotactic body radiotherapy (SBRT) to treat pancreatic cancer. Challenges in delivering SBRT include close proximity of several organs at risk (OARs) and target volume inter and intra fraction positional variations. Magnetic resonance image (MRI) guided radiotherapy has shown potential for online adaptive radiotherapy for pancreatic cancer, with superior soft tissue contrast compared to CT. The aim of this study was to investigate the variability of target and OAR volumes for different treatment approaches for pancreatic cancer, and to assess the suitability of utilizing a treatment-day MRI for treatment planning purposes. Ten healthy volunteers were scanned on a Siemens Skyra 3 T MRI scanner over two sessions (approximately 3 h apart), per day over 5 days to simulate an SBRT daily simulation scan for treatment planning. A pretreatment scan was also done to simulate patient setup and treatment. A 4D MRI scan was taken at each session for internal target volume (ITV) generation and assessment. For each volunteer a treatment plan was generated in the Raystation treatment planning system (TPS) following departmental protocols on the day one, first session dataset (D1S1), with bulk density overrides applied to enable dose calculation. This treatment plan was propagated through other imaging sessions, and the dose calculated. An additional treatment plan was generated on each first session of each day (S1) to simulate a daily replan process, with this plan propagated to the second session of the day. These accumulated mock treatment doses were assessed against the original treatment plan through DVH comparison of the PTV and OAR volumes. The generated ITV showed large variations when compared to both the first session ITV and daily ITV, with an average magnitude of 22.44% ± 13.28% and 25.83% ± 37.48% respectively. The PTV D95 was reduced by approximately 23.3% for both plan comparisons considered. Surrounding OARs had large variations in dose, with the small bowel V30 increasing by 128.87% when compared to the D1S1 plan, and 43.11% when compared to each daily S1 plan. Daily online adaptive radiotherapy is required for accurate dose delivery for pancreas cancer in the absence of additional motion management and tumour tracking techniques.


  • Open Access

    Assessment of intrafraction motion and its dosimetric impact on prostate radiotherapy using an in-house developed position monitoring system

    by Sankar Arumugam, Tony Young, Viet Do, Phillip Chlap, Christine Tawfik, Mark Udovitch, Karen Wong, Mark Sidhom

    Purpose: To implement an in-house developed position monitoring software, SeedTracker, for conventional fractionation prostate radiotherapy, and study the effect on dosimetric impact and intrafraction motion.Methods: Thirty definitive prostate radiotherapy patients with implanted fiducial markers were included in the study. All patients were treated with VMAT technique and plans were generated using the Pinnacle planning system using the 6MV beam model for Elekta linear accelerator. The target dose of 60 Gy in 20 fractions was prescribed for 29 of 30 patients, and one patient was treated with the target dose of 78 Gy in 39 fractions. The SeedTracker position monitoring system, which uses the x-ray images acquired during treatment delivery in the Elekta linear accelerator and associated XVI system, was used for online prostate position monitoring. The position tolerance for online verification was progressively reduced from 5 mm, 4 mm, and to 3 mm in 10 patient cohorts to effectively manage the treatment interruptions resulting from intrafraction motion in routine clinical practice. The delivered dose to target volumes and organs at risk in each of the treatment fractions was assessed by incorporating the observed target positions into the original treatment plan.Results: In 27 of 30 patients, at least one gating event was observed, with a total of 177 occurrences of position deviation detected in 146 of 619 treatment fractions. In 5 mm, 4 mm, and 3 mm position tolerance cohorts, the position deviations were observed in 13%, 24%, and 33% of treatment fractions, respectively. Overall, the mean (range) deviation of -0.4 (-7.2 to 5.3) mm, -0.9 (-6.1 to 15.6) mm, and -1.7 (-7.0 to 6.1) mm was observed in Left-Right, Anterior-Posterior, and Superior-Inferior directions, respectively. The prostate CTV D99 would have been reduced by a maximum value of 1.3 Gy compared to the planned dose if position deviations were uncorrected, but with corrections, it was 0.3 Gy. Similarly, PTV D98 would have been reduced by a maximum value of 7.6 Gy uncorrected, with this difference reduced to 2.2 Gy with correction. The V60 to the rectum increased by a maximum of 1.0% uncorrected, which was reduced to 0.5%.Conclusion: Online target position monitoring for conventional fractionation prostate radiotherapy was successfully implemented on a standard Linear accelerator using an in-house developed position monitoring software, with an improvement in resultant dose to prostate target volume.


  • Open Access

    Reducing the margin in prostate radiotherapy: optimizing radiotherapy with a general-purpose linear accelerator using an in-house position monitoring system

    by Sankar Arumugam, Karen Wong, Viet Do, Mark Sidhom

    Purpose: To study the feasibility of optimizing the Clinical Target Volume to Planning Target Volume (CTV-PTV) margin in prostate radiotherapy(RT) with a general-purpose linear accelerator using an in-house developed position monitoring system, SeedTracker.Methods: A cohort of 30 patients having definitive prostate radiotherapy treated within an ethics-approved prospective trial was considered for this study. The intrafraction prostate motion and the position deviations were measured using SeedTracker system during each treatment fraction. Using this data the CTV-PTV margin required to cover 90% of the patients with a minimum of 95% of the prescription dose to CTV was calculated using van Herk’s formula. The margin calculations were performed for treatment scenarios both with and without applying the position corrections for observed position deviations. The feasibility of margin reduction with real-time monitoring was studied by assessing the delivered dose that incorporates the actual target position during treatment delivery and comparing it with the planned dose. This assessment was performed for plans generated with reduced CTV-PTV margin in the range of 7mm-3mm.Results: With real-time monitoring and position corrections applied the margin of 2.0mm, 2.1mm and 2.1mm in LR, AP and SI directions were required to meet the criteria of 90% population to receive 95% of the dose prescription to CTV. Without position corrections applied for observed position deviations a margin of 3.1mm, 4.0mm and 3.0mm was required in LR, AP and SI directions to meet the same criteria. A mean ± SD reduction of 0.5 ± 1.8% and 3 ± 7% of V60 for the rectum and bladder can be achieved for every 1mm reduction of PTV margin. With position corrections applied, the CTV D99 can be delivered within -0.2 ± 0.3 Gy of the planned dose for plans with a 3mm margin. Without applying corrections for position deviations the CTV D99 was reduced by a maximum of 1.1 ± 1.1 Gy for the 3mm margin plan and there was a statistically significant difference between planned and delivered dose for 3mm and 4mm margin plans.Conclusion: This study demonstrates the feasibility of reducing the margin in prostate radiotherapy with SeedTracker system without compromising the dose delivery accuracy to CTV while reducing dose to critical structures.


  • Open Access

    The delivered dose assessment in pancreas SBRT with the target position determined using an in-house position monitoring system

    by Sankar Arumugam, Tony Young, Meredith Johnston, Darren Pavey, Mark Lee

    Purpose: This study assessed the delivered dose accuracy in pancreas SBRT by incorporating the real-time target position determined using an in-house position monitoring system.Methods and materials: An online image-based position monitoring system, SeedTracker, was developed to monitor radiopaque marker positions using monoscopic x-ray images, available from the Elekta XVI imaging system. This system was applied to patients receiving SBRT for pancreatic cancer on the MASTERPLAN Pilot trial (ACTRN 12617001642370). All patients were implanted pre-treatment with at least three peri-tumoral radiopaque markers for target localisation. During treatment delivery, marker positions were compared to expected positions delineated from the planning CT. The position tolerance of ±3mm from the expected position of the markers was set to trigger a gating event (GE) during treatment. The dosimetric impact of position deviations and actual dose delivered with position corrections was assessed by convolving the plan control point dose matrices with temporal target positions determined during treatment.Results: Eight patients were treated within this study. At least one GE was observed in 38% of the treatment fractions and more than one GE was observed in 10% of the fractions. The position deviations resulted in the mean(range) difference of -0.1(-1.1 - 0.4)Gy in minimum dose to tumour and 1.9(-0.1- 4.6)Gy increase to Dmax to duodenum compared to planned dose. In actual treatment delivery with the patient realignment, the mean difference of tumour min dose and duodenal Dmax was reduced to 0.1(-1.0 – 1.1)Gy and 1.1 (-0.7 - 3.3)Gy respectively compared to the planned dose.Conclusions: The in-house real-time position monitoring system improved the treatment accuracy of pancreatic SBRT in a general-purpose linac and enabled assessment of delivered dose by incorporating the temporal target position during delivery. The intrafraction motion impacts the dose to tumour even if target position is maintained within a 3mm position tolerance.